Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Apr 29:13:904689.
doi: 10.3389/fimmu.2022.904689. eCollection 2022.

Commentary: Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens

Affiliations
Comment

Commentary: Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens

Josep M Llibre et al. Front Immunol. .
No abstract available

Keywords: C-reactive protein; IL-6; antiretroviral therapy; biomarkers; d-dimer; dolutegravir/lamivudine; inflammation; sCD14.

PubMed Disclaimer

Conflict of interest statement

JL has received payments or honoraria for lectures, presentations, or speaker’s bureaus from Janssen-Cilag, Gilead Sciences, and ViiV Healthcare, outside of the present work. PC has received research grants from Richmond and ViiV Healthcare, consulting fees from ViiV Healthcare; has received honoraria for speaker fees from ViiV Healthcare and Novartis; and has participated in data safety monitoring/advisory boards for Moderna, ViiV Healthcare, and Merck. TB has received conference support, speaker fees, and advisory board honoraria from Gilead Sciences, Janssen, MSD, Roche, Theratech, and ViiV Healthcare, and holds research and educational grants from Gilead Sciences, Roche, and ViiV Healthcare.

Comment on

References

    1. Serrano-Villar S, López-Huertas MR, Jiménez D, Galera C, Martínez-Sanz J, Moreno E, et al. . Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens. Front Immunol (2022) 13:848630. doi: 10.3389/fimmu.2022.848630 - DOI - PMC - PubMed
    1. European AIDS Clinical Society . EACS Guidelines. Version 11.0 (2021). Available at: http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html (Accessed March 24, 2022).
    1. Saag MS, Gandhi RT, Hoy JF, Landovitz RJ, Thompson MA, Sax PE, et al. . Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel. JAMA - J Am Med Assoc (2020) 324:1651–69. doi: 10.1001/jama.2020.17025 - DOI - PMC - PubMed
    1. Panel on Antiretroviral Guidelines for Adults and Adolescents . Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV. Department of Health and Human Services. Available at: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Ad... (Accessed March 24, 2022).
    1. Hunt PW, Lee SA, Siedner MJ. Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection. J Infect Dis (2016) 214:S44–50. doi: 10.1093/infdis/jiw275 - DOI - PMC - PubMed